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Evaluation of novel CEX resin for continuous 
processing of Mab purification 
 Takuya Muramoto, Ph. D 
Bio-manufacturing Technology Laboratories, CMC center 
Abstract 
• We have evaluated novel cation exchange resin and membrane which is potentially suited for continuous 
process in biologics manufacturing. 
• Typically cation exchange chromatography (CEX) is used in a bind/elute (B/E) mode for the MAb process 
since MAb act as cation at the buffer condition used for CEX due to the pI from neutral to weak basic. 
Generally, purpose of CEX chromatography is to remove aggregates and other impurities like HCP and 
DNA. Especially, aggregate removal is of interest to the industries. A continuous process in MAb 
downstream process can solve several bottlenecks in typical batch process. However its capability cannot 
be fully utilized if some step of chromatography is used in a B/E mode since it will take a longer process 
time due to the posing of product stream for binding and washing and it will take a more cost due to the 
requirement of large amount of resins as we use at the batch process. In such a case, chromatography in 
flowthrough mode has a potential to overcome those issues for both cost and time and enables us to 
develop more streamlined continuous process.  
• We will present the result of our study to evaluate novel CEX resin developed by EMD Millipore (The Life 
Science division of Merck KGaA, Darmstadt, Germany) by comparing with the existing process of Mab A 
and we obtained a conclusion that this resin is fitted to the continuous processing very much. The novel 
resin showed a better impurity clearance than our existing process. For example, over 65% removal of 
aggregate by the novel resin was obtained in contrast to no removal by the existing process. A 20-fold 
better clearance for DNA was confirmed for the novel resin than the existing process. This indicates an 
additional polishing step can be omitted and this new chromatography can be a strong option if we 
need to reduce such impurities further. Also the resin cost is expected to be reduced down to 1/10 in 
maximum since those impurity clearance results were obtained about 10-times larger load than the 
typical B/E mode operation of CEX. Considering those aspects, we conclude that this resin showed a 
better fit for a continuous process. We will also discuss an expected effect of the novel CEX resin on cost 
and process time savings by a continuous process. 
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Background 
• Typically in mAb purification process, CEX 
chromatography is operated in bind/elute 
mode due to the isoelectric point of mAb 
(pI 7-9). 
• CEX removes aggregates, fragments, and 
HCP efficiently. 
• Recently, CEX resin for flow/through 
mode has been developed in some 
companies. 
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Protein A CEX 
Virus filtration Ultra/Diafiltratoin AEX 
Flow/through Bind/Elute Bind/Elute 
Load                        ,Wash1,   Elution, Strip, Reg, Equ1, Equ2 
Chromatogram of Current CEX step 
CEX Flow/through technology 
 Bind impurities Smaller volume of resin or membrane 
     (HCP, DNA, Aggregate)  Single-use compliant 
 Less steps "Green" process 
     (no wash, elution step)   Less process development needed 
  Less buffer number (fewer steps) 
  Reduced buffer consumption                                            
 Easily applicable to continuous processing 
 CEX  AEX  Virus filtration  (tank less, hold less) 
 Processing time and in-process holding tanks can be reduced 
 Smaller column can be used 
                      
 Evaluation of novel CEX adsorber 
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Chromatogram of novel CEX resin  
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Column volume: 1mL (0.8 cm ID x 2 cm H) 
Load sample: Mab A CEX Load 25 mg/mL (2-fold dilution according to conditions 
 vendor recommended, pH5, 3.2 mS/cm ) 
Load amount: 1300 mg/mL-resin 
Flow rate: 0.33 mL/min (Residence time: 3 min) 
Equilibration                           Flow through                               Strip (1M NaCl) 
Impurity removal property 
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• Efficient reduction of impurities was observed as the manufacturer's information. 
• Aggregates and Fragments gradually increased as amount of load. However, significant 
breakthrough of impurities was not observed under the tested condition. 
SEC analysis 
Load, Flow through Pool, Strip sample 
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            Load                         Flow through Pool                          Strip 
Load:    98.9% monomer, 0.3% HMW, 0.8% LMW 
Flow through:  99.1% monomer, 0.06% HMW, 0.9% LMW 
Strip:    94.5% monomer, 4.0% HMW, 1.5% LMW 








(ppb) HMW Monomer LMW 
Current process -Bind/Elute- 
Load - 0.2 99.0 0.7 1200 66 
Eluate 97 0.3 99.0 0.6 230 0.3 
Novel resin –Flowthrough- 
Load - 0.3 98.8 0.9 400 160 














• Impurity removal capability by novel CEX F/T resin was comparable or better 
than by current CEX process with vendor-recommended conditions as the 
first evaluation. 
 
• Resin volume can be reduced for about 1/10 
 Current CEX process is operated in Bind/Elute mode with Capacities < 100 
g/L-resin. Merck CEX resin is operated in Flowthrough mode with 
Capacities > 1000 g/L, which allows for a smaller CEX column (up to 90% 
reduction) 
 For example, 60 cm ID x 20 cm  20 cm ID x 20 cm 
• Reduce buffer number and fluid volume depending on column size 
 






 Optimize sample loading condition (pH, conductivity, flowrate, etc.) 
 Continue to explore further candidates for CEX F/T mode 
 Application to continuous processing 
 Coupling of CEX and AEX step 
 Buffer selection which is suitable for in-line conditioning (pH and conductivity) 
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